Form 4: Rapport Therapeutics CMO Granted 130,000 Stock Options

Rapport Therapeutics' Chief Medical Officer, Jeffrey Sevigny, was granted 130,000 stock options with an exercise price of $27.75, vesting over four years.

Summary

• Jeffrey Sevigny, Chief Medical Officer of Rapport Therapeutics, Inc. (RAPP), was granted 130,000 stock options.
• The options have an exercise price of $27.75 per share.
• The grant date for these options was February 2, 2026.
• The shares underlying the option will vest in 48 equal monthly installments following January 1, 2026.
• Vesting is contingent upon Mr. Sevigny's continued service to the company on each vesting date.
• The options have an expiration date of February 2, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a routine executive compensation action that aligns the Chief Medical Officer's financial interests with the long-term performance of the company, without indicating any immediate operational or financial changes.

Positives

• The grant of 130,000 stock options to the Chief Medical Officer aligns executive incentives with shareholder interests, encouraging long-term commitment and performance.

Risks

• The value of the stock options is subject to the future market price of Rapport Therapeutics, Inc. common stock, which may fluctuate and could be below the exercise price, rendering the options worthless.
• Vesting of the options is dependent on the Reporting Person's continued service, posing a risk if employment ceases before full vesting.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, beyond the vesting schedule of the granted options.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, designed to attract and retain key talent while aligning management's long-term interests with those of shareholders. Such grants are particularly prevalent in growth-oriented companies like Rapport Therapeutics, Inc., where future success is heavily reliant on scientific and clinical leadership.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, vary widely across the biotechnology sector based on company stage, market capitalization, and the executive's role and experience. While specific comparable grants are not detailed in this filing, a grant of 130,000 options to a Chief Medical Officer is within the typical range for a company of Rapport Therapeutics' profile, aiming to incentivize long-term value creation.
• The 4-year monthly vesting schedule is a standard practice, similar to those observed at peer companies such as Sage Therapeutics or Karuna Therapeutics for their senior executives, promoting sustained commitment.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can be seen as a positive for shareholders, as it incentivizes the Chief Medical Officer to work towards increasing the company's stock value over the long term.
• Employees: This filing specifically pertains to a senior executive's compensation and does not directly impact the broader employee base, though it reflects the company's compensation strategy for leadership.

Next Steps

• The stock options will vest in 48 equal monthly installments following January 1, 2026, subject to continued service.

Key Dates

Keywords

Rapport Therapeutics, RAPP, stock option, insider transaction, Form 4, Jeffrey Sevigny, Chief Medical Officer, executive compensation, equity grant